Press release
Chronic Liver Disease Market is projected to reach USD 22.31 billion by 2034
Chronic Liver Disease
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71133
Chronic liver disease includes a spectrum of progressive hepatic disorders that lead to inflammation, fibrosis, cirrhosis, portal hypertension, and potential progression to hepatocellular carcinoma (HCC). Early detection and timely intervention significantly reduce mortality, but limited treatment options for fibrosis reversal continue to create unmet clinical need.
Key Market Highlights
• 2024 Market Size: USD 12.84 billion
• 2034 Forecast: USD 22.31 billion
• CAGR (2025-2034): 5.9%
• Largest Segment: MASLD/MASH & viral hepatitis-related CLD
• Fastest-Growing Segment: Antifibrotic therapies and AI-powered diagnostics
Epidemiology & Clinical Insights
1. Global Burden
• Chronic liver disease affects ~1.5 billion people worldwide.
• CLD-related deaths are among the top 10 causes of mortality globally.
• The highest growth segments are metabolic liver disease and alcohol-related hepatitis.
2. Major Etiologies
• Viral hepatitis (HBV, HCV)
• MASLD/MASH (formerly NAFLD/NASH)
• Alcohol-related liver disease (ARLD)
• Autoimmune hepatitis (AIH)
• Primary biliary cholangitis (PBC)
• Primary sclerosing cholangitis (PSC)
• Genetic/metabolic disorders (hemochromatosis, Wilson's disease)
3. Stages of Disease
• Steatosis
• Hepatitis (inflammatory stage)
• Fibrosis (mild to advanced)
• Cirrhosis (compensated/decompensated)
• Liver failure
• Hepatocellular carcinoma (HCC)
4. Diagnostic Tools
• Liver ultrasound & elastography (FibroScan)
• MRI-PDFF, MR elastography
• Serum biomarkers (FIB-4, ELF score)
• Liver biopsy (gold standard)
• AI-based fibrosis prediction models
Market Growth Drivers
1. Rising Prevalence of Metabolic Liver Disease
Global obesity, diabetes, and metabolic syndrome trends are driving MASLD/MASH cases sharply upward.
2. Advances in Non-Invasive Diagnostic Technologies
Ultrasound elastography, AI imaging, and biomarker panels reduce dependence on biopsy.
3. Strong Pipeline of Antifibrotic Therapies
Multiple drugs targeting stellate cell pathways and inflammation are in late-stage development.
4. Government Efforts to Eliminate Hepatitis B & C
Screening programs increase diagnosis and treatment demand.
5. Increasing Alcohol Consumption Worldwide
Particularly in Europe, North America, and parts of Asia, expanding ARLD incidence.
Market Restraints
• Lack of effective FDA-approved antifibrotic therapies
• Late diagnosis of fibrosis and cirrhosis
• CLD progression remains irreversible in advanced stages
• High treatment cost for viral hepatitis and complications
• Limited access to specialist hepatology care in developing regions
Market Opportunities
1. Antifibrotic & Regenerative Therapies
Targets include:
• TGF-β pathway
• CCR2/CCR5 inhibitors
• FXR agonists
• Mitochondrial modulators
2. Digital Liver Health Monitoring
Wearables + AI platforms tracking:
• ALT/AST trends
• Fibrosis progression
• Medication adherence
3. Liquid Biopsy Solutions
Detection of fibrosis, cirrhosis, and early HCC via ctDNA and proteomic biomarkers.
4. Precision Hepatology
Patient-specific molecular profiles for individualized therapy.
5. Expansion of Hepatitis C Curative Therapies
DAAs with >95% cure rates fueling adoption in developing regions.
Segmentation Overview
By Disease Type
• Viral hepatitis (HBV, HCV)
• MASLD/MASH
• Alcohol-related liver disease
• Autoimmune liver diseases (AIH, PBC, PSC)
• Genetic/metabolic liver diseases
• Other chronic liver disorders
By Treatment
• Antivirals
• Immunosuppressive agents
• Antifibrotic therapies (emerging)
• Supportive care
• Liver transplantation
By Diagnostic Modality
• Imaging (US, CT, MRI, elastography)
• Blood biomarkers
• Liver biopsy
• AI-based diagnostic tools
By End User
• Hospitals
• Hepatology clinics
• Diagnostic centers
• Research institutions
Explore Full Report here: https://exactitudeconsultancy.com/reports/71133/chronic-liver-disease-market
Regional Insights
North America - Largest Market
High prevalence of obesity-related liver disease, strong adoption of advanced imaging, and broad hepatitis C treatment uptake.
Europe - Strong Antifibrotic R&D Ecosystem
Germany, France, Italy, UK lead liver fibrosis research, with major pharmaceutical pipeline investments.
Asia Pacific - Fastest Growing
High viral hepatitis burden + rising metabolic disease + expanding healthcare infrastructure.
Latin America - Emerging
Improved hepatitis screening and growing liver fibrosis diagnostics market.
Middle East & Africa - Developing
Increasing awareness of viral hepatitis elimination programs.
Competitive Landscape
Major companies leading the chronic liver disease therapeutics and diagnostics market include:
• Gilead Sciences
• AbbVie
• Novartis
• Roche
• AstraZeneca
• Intercept Pharmaceuticals
• Pfizer
• Merck & Co.
• Bristol Myers Squibb
• Galectin Therapeutics (antifibrotics)
• Madrigal Pharmaceuticals (metabolic liver disease)
Key focus areas: antifibrotic development, metabolic liver disease therapeutics, AI-driven fibrosis diagnostics, and hepatitis treatment expansion.
Recent Market Developments
• Breakthrough therapies in MASH/MASLD targeting inflammation and metabolism
• Adoption of elastography as frontline screening worldwide
• New AI algorithms for assessing fibrosis and cirrhosis
• Expansion of curative hepatitis C therapies in low-income countries
• Increase in clinical trials evaluating combination antifibrotic therapies
Future Outlook (2025-2034)
The Chronic Liver Disease Market will expand significantly as:
• Metabolic and alcohol-related liver diseases surge globally
• Advanced diagnostics reduce biopsy dependence
• Next-generation antifibrotic therapies enter the market
• Digital hepatology platforms improve long-term management
• Public health initiatives reduce hepatitis burden
By 2034, the market is expected to reach USD 22.31 billion, driven by rising disease prevalence and continued therapeutic innovation.
This report is also available in the following languages : Japanese (慢性肝疾患市場), Korean (만성 간 질환 시장), Chinese (慢性肝病市场), French (Marché des maladies chroniques du foie), German (Markt für chronische Lebererkrankungen), and Italian (Mercato delle malattie epatiche croniche), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71133
Our More Reports:
Digital Therapeutics and Wellness Market
https://exactitudeconsultancy.com/reports/75787/digital-therapeutics-and-wellness-market
Nebuliser Market
https://exactitudeconsultancy.com/reports/75867/nebuliser-market
Gout Therapeutics Market
https://exactitudeconsultancy.com/reports/75888/gout-therapeutics-market
NAM Home Health Care Providers Market
https://exactitudeconsultancy.com/reports/75947/nam-home-health-care-providers-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Liver Disease Market is projected to reach USD 22.31 billion by 2034 here
News-ID: 4310967 • Views: …
More Releases from Exactitude Consultancy
Birch Allergy Market was valued at USD 1.45 billion in 2024 and is projected to …
The Birch Allergy Market was valued at USD 1.45 billion in 2024 and is projected to reach ~USD 2.62 billion by 2034, growing at a CAGR of around 6.1%. Rising prevalence of seasonal allergies, improved diagnostic awareness, and the increasing use of immunotherapy are the primary factors fueling market growth.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71309
Key Market Drivers
• Higher incidence of birch pollen allergies in North America and Europe.
• Growing…
Autoimmune Hepatitis (AIH) Market is projected to reach USD 1.98 billion by 2034
The global Autoimmune Hepatitis Market was valued at USD 1.14 billion in 2024 and is projected to reach USD 1.98 billion by 2034, registering a CAGR of 5.7% during the forecast period (2025-2034). Growth is driven by rising diagnosis rates of chronic autoimmune liver diseases, increased use of corticosteroids and immunomodulators, advancements in serologic and histologic diagnostics, and growing research interest in novel biologic therapies for steroid-refractory patients.
Download Full PDF…
Axial Spondyloarthritis (axSpA) Market was valued at ~USD 6.3 billion in 2024 an …
Axial Spondyloarthritis (axSpA) Market Overview (Short & Clean)
The Axial Spondyloarthritis (axSpA) market was valued at ~USD 6.3 billion in 2024 and is projected to reach ~USD 11.8 billion by 2034, registering a CAGR of around 6.7%. Rising diagnosis of non-radiographic axSpA, increased awareness among rheumatologists, and rapid adoption of biologics are the main factors driving growth.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71307
Key Market Drivers
• Growing recognition of non-radiographic axSpA…
Adult-onset Still Disease (AOSD) market growing at a CAGR of around 7.7%
The Adult-onset Still Disease (AOSD) market was valued at ~USD 1.2 billion in 2024 and is projected to reach ~USD 2.5 billion by 2034, growing at a CAGR of around 7.7%. Rising diagnosis rates, improved biomarker-based testing, and strong adoption of biologics are the primary growth drivers.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71305
Key Market Drivers
• Increasing awareness and improved identification of AOSD cases.
• Growing use of IL-1 and IL-6 inhibitors…
More Releases for Liver
Rising Liver Disease Cases Drive Growth In Liver Metastases Treatment Market Dri …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Liver Metastases Treatment Market Size By 2025?
The market for treating liver metastases has seen significant growth in the past few years. It is projected to increase from $1.57 billion in 2024 to $1.71 billion in 2025, with a compound annual growth rate (CAGR) of…
LivCare Liver Support
The liver plays a crucial role in maintaining overall well-being, performing essential functions like detoxification, digestion, and metabolism. However, many people overlook the importance of liver health until problems arise. LivCare Liver Support is a premium supplement designed to keep your liver in peak condition. By incorporating this supplement into your daily routine, you can help ensure your liver functions optimally, leading to better overall health.
● Product Name - LivCare…
Liver Cancer Therapeutics Market - Empowering Recovery, Restoring Health: Innova …
Newark, New Castle, USA - new report, titled Liver Cancer Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Liver Cancer Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Liver Cancer Therapeutics market. The report offers an overview of…
Liver Health Supplements Market Grows Strong as Consumers Adopt Proactive Measur …
Global liver health supplements market was valued at US$ 8.7 Bn in 2021, is growing at an estimated CAGR of 5.8% over the forecast period (2022 - 2030). The liver health supplements market is growing due to the increasing awareness of the importance of liver health and the rise of lifestyle-related liver diseases. The market offers a wide range of supplements that help in improving liver function, supporting liver detoxification,…
Urgent Liver 911 Reviews 2021: Is Urgent Liver 911 Legit?
Urgent Liver 911 by PhytAge Laboratories is a powerful diet that promotes liver function by combining natural minerals and nutrients. The diet is made up of plant and herbal extracts that collectively aid in liver cell protection. While the liver is an important human organ that promotes general health and vitality, most people are unaware that even those who appear to be in good health can be affected by liver…
Liver Extract Power Exporter, Liver Extract Product, Liver Extract Crude, Liver …
Titan Biotech is an ISO 9001:2000 Certified Company, established with an objective of serving Scientific Community and providing good quality of Biological Products, Biotechnology Products, Biological Extracts and their derivatives. Liver Extract Power Exporter is produced from specific fraction of beef liver. Liver Extract is rich in vital nutrients including energy producing B Vitamins and serve as an excellent source of proteins. Liver Extract is capable of stimulating the production…
